ZIOPHARM Oncology, Inc. and Intrexon Corporation Announce Preclinical Study Results at 2011 ASGCT Meeting from Controlled In Vivo Expression of Genes with Broad and Potent Antitumor Activity

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), and Intrexon Corporation announced today that results from two preclinical studies examining the tightly controlled, intra-tumoral expression of a novel protein, interleukin-12 (IL-12), in melanoma, colon, lung, leukemia, breast and pancreatic cancer models in mice, were presented at the 2011 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 18 – 21 in Seattle, Washington.